Despite the large number of studies that have supported the identification of new potential targets for migraine prevention therapy over time, it should be emphasized that the related new drugs has also resulted in unexpected failures like in the latest striking case of the antibodies inhibiting PAC1 receptor of PACAP38 [46,180]. This evidence concerns the gene ADCYAP1 and migraine disorder.